STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion

Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, has raised funding at a $1.8 billion valuation. The company aims to add 10 healthy years to human lifespan through gene therapies and cell replacement therapies. The company is currently running its first clinical trial for an Alzheimer's disease treatment, with positive results and data expected around August.